InMed amends ATM equity offering agreement with H.C. Wainwright

InMed Pharmaceuticals Inc.

Amendment to April 2022 at-the-market offering agreement with H.C. Wainwright & Co.
Settlement cycle updated to T+1 (first trading day) to reflect current market rules.
New data privacy compliance representation added; $50k cap on agent's counsel fees reimbursed.
Company to file a prospectus supplement and deliver customary closing deliverables on June 27, 2024.
Prior letter agreements from October 2023 and June 2024 remain effective unless conflicting with amended ATM.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.